Open Nav

Please submit your session questions in advance at

Alnylam Pharmaceuticals

Alnylam is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of patients who have limited or inadequate treatment options. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of debilitating diseases with high unmet medical need. Alnylam was founded in 2002 on a bold vision to turn scientific possibility into reality, which is now marked by its robust discovery platform and deep pipeline of investigational medicines, including multiple programs in late-stage clinical development.

  • Date:Monday, February 11
  • Time:1:30 PM - 1:45 PM
  • Room:Herald/Soho
  • Location:7th Floor
  • Session Type:Company Presentation
  • Submission ID:23336
  • Company Presentation - Presentation Type:Publicly Traded Company
  • Goal for Presentation:Enhance awareness of Alnylam's approved product, robust pipeline, and platform progression.
  • Company Website:
  • Company HQ City:Cambridge
  • Company HQ State:Massachusetts
  • Company HQ Country:United States
  • Ticker:ALNY
  • Exchange:NASDAQ
  • CEO/Top Company Official:John Maraganore
  • Year Founded:2002
  • Main Therapeutic Focus:Multiple Therapeutics
  • Lead Product in Development:ONPATTRO, approved product. Givosiran Ph3 results in 2019.
  • Development Phase of Primary Product:Multiple Products in Market
Josh Brodsky
Alnylam Pharmaceuticals, Inc.